RxDoctor Payments Data

Amier Ahmad, MD

Clinical Cardiac Electrophysiology · Sunnyside, WANPI 1689061897

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (52.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 67.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $26,116 and has fallen 78.9% since, to $5,499 in 2025.

$57,936in general payments, 2019–2025

Across 266 payments — averaging $217.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$39K
  • Medtronic$13K
  • Boston Scientific$2K
  • Philips North America LLC$1K
  • Biosense Webster, Inc.$606
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$267
  • plus $2K from 17 others

What the payments were for

  • Grants$30,31852%
  • Travel & lodging$15,58527%
  • Food & beverage$11,32820%
  • Education$7051%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,936 in reported general payments places this provider in the 85th percentile of 68 clinical cardiac electrophysiology providers in Washington.

See all clinical cardiac electrophysiology providers in Washington

Medicare billing

Part B allowed, 2024
$31,504
Medicare patients
133
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$47,203
XareltoRivaroxaban19$17,361
Repatha SureclickEvolocumab13$7,105
Flecainide Acetate33$1,066
Metoprolol Succinate63$559
ClopidogrelClopidogrel Bisulfate24$422
Amiodarone Hcl26$356
Atorvastatin Calcium37$213
Carvedilol14$170
Losartan Potassium13$131
Lisinopril20$123
Rosuvastatin Calcium24$119
Amlodipine Besylate16$95
Metoprolol Tartrate12$64
Furosemide11$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$138$47,20345 claims
Johnson & JohnsonXarelto$190$17,36119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 clinical cardiac electrophysiology providers in Washington.

Other clinical cardiac electrophysiology in Sunnyside

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →